Literature DB >> 27640138

Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials.

Melvin Lee Kiang Chua1, Sze Huey Tan2, Grace Kusumawidjaja3, Ma Than Than Shwe3, Shie Lee Cheah3, Kam Weng Fong4, Yoke Lim Soong4, Joseph Tien Seng Wee4, Terence Wee Kiat Tan4.   

Abstract

PURPOSE: To assess the prognostic value of neutrophil-to-lymphocyte ratio (NLR) in patients with International Union Against Cancer (UICC)-staged III/IVA,B nasopharyngeal carcinoma (NPC), who were enrolled into two randomised controlled trials of concurrent/adjuvant chemotherapy when added to radiotherapy (SQNP01), and induction chemotherapy when added to chemoradiotherapy (NCC0901).
MATERIAL AND METHODS: A post hoc analysis of pooled cohorts from SQNP01 (N = 221) and NCC0901 (N = 172) was performed. We employed a threshold of pre-treatment NLR = 3.0 (median) to stratify patients. Survival outcomes were compared using log-rank test. Multivariable Cox regression analyses were performed to assess association between NLR and overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS).
RESULTS: High NLR (≥3.0) was associated with advanced T-status (p = 0.002), N-status (p = 0.002), overall UICC stage (p = 0.004), and high pre-treatment Epstein-Barr virus DNA titre (p = 0.001). High NLR was not associated with OS (0.94 [0.67-1.32], p = 0.7), DFS (0.98 [0.73-1.33], p = 0.9), DMFS (1.02 [0.66-1.57], p = 0.9), and LRFS (1.37 [0.84-2.22], p = 0.2) on univariable and multivariable analyses, while conventional clinical indices (T-status, N-status, and overall UICC stage) were prognostic of clinical outcomes. High NLR also did not predict for a treatment effect with the experimental arms in both trials.
CONCLUSION: Our pooled analyses that were confined to a homogenous patient population of locally advanced NPC do not suggest that NLR adds prognostic value to conventional clinical indices in identifying patients with unfavourable disease.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarker; Locally advanced; Nasopharyngeal carcinoma; Neutrophil-to-lymphocyte ratio; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27640138     DOI: 10.1016/j.ejca.2016.08.006

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  21 in total

Review 1.  The 'Danse Macabre'-Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes.

Authors:  Sara Hadjigol; Bansari A Shah; Neil M O'Brien-Simpson
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

2.  Systemic immune-inflammation index as a prognostic marker in patients with newly diagnosed metastatic nasopharyngeal carcinoma: a propensity score-matched study.

Authors:  Cheng Lin; Sheng Lin; Qiao-Juan Guo; Jing-Feng Zong; Tian-Zhu Lu; Na Lin; Shao-Jun Lin; Jian-Ji Pan
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

3.  Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis.

Authors:  Yukinori Takenaka; Takahiro Kitamura; Ryohei Oya; Naoki Ashida; Kotaro Shimizu; Kazuya Takemura; Yoshifumi Yamamoto; Atsuhiko Uno
Journal:  PLoS One       Date:  2017-07-17       Impact factor: 3.240

4.  Pretreatment combination of platelet counts and neutrophil-lymphocyte ratio predicts survival of nasopharyngeal cancer patients receiving intensity-modulated radiotherapy.

Authors:  Yu-Hsuan Lin; Kuo-Ping Chang; Yaoh-Shiang Lin; Ting-Shou Chang
Journal:  Onco Targets Ther       Date:  2017-05-26       Impact factor: 4.147

5.  Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.

Authors:  Jianpei Li; Shulin Chen; Songguo Peng; Yijun Liu; Shan Xing; Xia He; Hao Chen
Journal:  Int J Biol Sci       Date:  2018-04-05       Impact factor: 6.580

6.  Exploration and validation of radiomics signature as an independent prognostic biomarker in stage III-IVb nasopharyngeal carcinoma.

Authors:  Fu-Sheng Ouyang; Bao-Liang Guo; Bin Zhang; Yu-Hao Dong; Lu Zhang; Xiao-Kai Mo; Wen-Hui Huang; Shui-Xing Zhang; Qiu-Gen Hu
Journal:  Oncotarget       Date:  2017-08-24

7.  A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma.

Authors:  Yajing Zhang; Yujie Zhu; Jiaqi Wang; Yi Xu; Zekun Wang; Yang Liu; Xuebing Di; Lin Feng; Ye Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-08-03       Impact factor: 6.968

8.  Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy.

Authors:  Shu-Hui Lv; Wang-Zhong Li; Hu Liang; Guo-Ying Liu; Wei-Xiong Xia; Yan-Qun Xiang
Journal:  J Inflamm Res       Date:  2021-05-25

9.  Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.

Authors:  Yun-Hsuan Lin; Tai-Lin Huang; Chih-Yen Chien; Hui-Chun Chen; Hsuan-Chih Hsu; Eng-Yen Huang; Chong-Jong Wang; Yu-Jie Huang; Yu-Ming Wang; Chun-Chieh Huang; Shang-Yu Chou; Kuan-Cho Liao; Fu-Min Fang
Journal:  Radiat Oncol       Date:  2018-03-20       Impact factor: 3.481

10.  Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma.

Authors:  Yanming Jiang; Song Qu; Xinbin Pan; Shiting Huang; Xiaodong Zhu
Journal:  Oncotarget       Date:  2018-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.